| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3aaf20464e8f944ac00da67540487ba2 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-726 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57488
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-76 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-76 |
| filingDate |
2016-04-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d95694e76c846c29df4be8420245b3e0 |
| publicationDate |
2016-10-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2016162037-A1 |
| titleOfInvention |
Lhcgr for use in diagnosing and monitoring of andrological diseases |
| abstract |
The present invention relates to a method for predicting for a male subject atrisk of having, developing or relapse oftestis cancer; and/or prostate cancer; and/or a need of Androgen replacement therapy (ART); and/or gonadal dysfunction. The method is based on the measurement of the level of LHCGR (LH/hCG receptor) in a biological sample from the male subject, such as a (blood) serum sample. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107024591-A |
| priorityDate |
2015-04-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |